227 related articles for article (PubMed ID: 16818623)
21. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
[TBL] [Abstract][Full Text] [Related]
22. Radiation induced thyroid cancer: fundamental and applied aspects.
Tronko M; Bogdanova T; Voskoboynyk L; Zurnadzhy L; Shpak V; Gulak L
Exp Oncol; 2010 Sep; 32(3):200-4. PubMed ID: 21403618
[TBL] [Abstract][Full Text] [Related]
23. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
24. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
Schmidt J; Derr V; Heinrich MC; Crum CP; Fletcher JA; Corless CL; Nosé V
Am J Surg Pathol; 2007 Sep; 31(9):1337-43. PubMed ID: 17721188
[TBL] [Abstract][Full Text] [Related]
25. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
26. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
Giordano TJ; Kuick R; Thomas DG; Misek DE; Vinco M; Sanders D; Zhu Z; Ciampi R; Roh M; Shedden K; Gauger P; Doherty G; Thompson NW; Hanash S; Koenig RJ; Nikiforov YE
Oncogene; 2005 Oct; 24(44):6646-56. PubMed ID: 16007166
[TBL] [Abstract][Full Text] [Related]
27. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
28. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells.
Fiore AP; Fuziwara CS; Kimura ET
Thyroid; 2009 Nov; 19(11):1249-56. PubMed ID: 19725779
[TBL] [Abstract][Full Text] [Related]
29. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.
Moretti S; Menicali E; Nucci N; Voce P; Colella R; Melillo RM; Liotti F; Morelli S; Fallarino F; Macchiarulo A; Santoro M; Avenia N; Puxeddu E
J Biol Chem; 2017 Feb; 292(5):1785-1797. PubMed ID: 27994058
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
31. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
32. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
33. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.
Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B
Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036
[TBL] [Abstract][Full Text] [Related]
34. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
35. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
36. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
37. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
38. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
[TBL] [Abstract][Full Text] [Related]
39. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
40. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
Castellone MD; Guarino V; De Falco V; Carlomagno F; Basolo F; Faviana P; Kruhoffer M; Orntoft T; Russell JP; Rothstein JL; Fusco A; Santoro M; Melillo RM
Oncogene; 2004 Aug; 23(35):5958-67. PubMed ID: 15184868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
